Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00047749 · ClinicalTrials.gov registry record · Phase 3
Prialt (Ziconotide) In Severe Chronic Pain
A Phase 3 study, sponsored by Elan Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 220
- Enrollment target
NCT00047749: Completed Phase 3 study, sponsored by Elan Pharmaceuticals.
NCT00047749 is a Phase 3 study that has completed, run by Elan Pharmaceuticals. The registered enrollment target is 220 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (72% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00047749, a Phase 3 study, has completed, sponsored by Elan Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 220 participants
- Enrollment target
Study Summary
The purpose of this study is to understand the effects of intrathecal ziconotide (an experimental pain medication) when the dose is slowly increased over a 3-week period in patients with severe chronic pain. During the weaning phase, the study will also gather information about switching from other intrathecal or IT medication (slowly pumped directly into the space around the spine) to other systemic pain medication (by mouth or through the skin using a patch). After being weaned off current IT medication, patients will be placed on IT ziconotide or placebo (non-active substance) as well as being allowed a stable dose of systemic pain medications. Patients who complete this study may be eligible for long-term ziconotide therapy via extension protocol ELN92045-352.
Interventions
- DRUG Prialt (ziconotide)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2002-08 |
| Est. Completion | 2003-06 |
| Phase | Phase 3 |
What the finished NCT00047749 record still lists
NCT00047749 is an interventional study that assigns participants to a tested intervention. The registered 220 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (72% lower).
The record links to 0 conditions, and to 1 intervention - of which Prialt (ziconotide) is the first listed.
NCT00047749 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00047749 about?
NCT00047749 is a clinical study titled "Prialt (Ziconotide) In Severe Chronic Pain". The purpose of this study is to understand the effects of intrathecal ziconotide (an experimental pain medication) when the dose is slowly increased over a 3-week period in patients with severe chronic pain. During the weaning phase, the study will also gather information about switching from other ...
What is the current status of trial NCT00047749?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 220 participants. The study started on 2002-08. Estimated completion is 2003-06.
What interventions are being tested in trial NCT00047749?
The interventions under investigation include: Prialt (ziconotide) (DRUG).
Who is sponsoring clinical trial NCT00047749?
This trial is sponsored by Elan Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00047749's enrollment target sits among peer trials
220 1318th of 2000 higher than 672 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00920972 · 220 participants · Phase 1
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
- NCT01851642 · 220 participants
Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
- NCT02582021 · 220 participants
WISE CVD - Continuation (WISE HFpEF)
- NCT04067830 · 220 participants · Phase 2
Respiratory Muscle Training Before Surgery in Preventing Lung Complications in Patients With Stage I-IIIB Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia